158 related articles for article (PubMed ID: 26083213)
1. Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease.
Monteleone G; Pallone F
N Engl J Med; 2015 Jun; 372(25):2461. PubMed ID: 26083213
[No Abstract] [Full Text] [Related]
2. Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease.
Kennedy BW
N Engl J Med; 2015 Jun; 372(25):2461. PubMed ID: 26083214
[No Abstract] [Full Text] [Related]
3. [Good results: antisense-oligonucleotide Mongersen is in Crohn's disease].
Moskaleva M
Dtsch Med Wochenschr; 2015 May; 140(10):710-1. PubMed ID: 26171473
[No Abstract] [Full Text] [Related]
4. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.
Monteleone G; Neurath MF; Ardizzone S; Di Sabatino A; Fantini MC; Castiglione F; Scribano ML; Armuzzi A; Caprioli F; Sturniolo GC; Rogai F; Vecchi M; Atreya R; Bossa F; Onali S; Fichera M; Corazza GR; Biancone L; Savarino V; Pica R; Orlando A; Pallone F
N Engl J Med; 2015 Mar; 372(12):1104-13. PubMed ID: 25785968
[TBL] [Abstract][Full Text] [Related]
5. Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?
Danese S; Fiorino G; Peyrin-Biroulet L
Gastroenterology; 2015 Oct; 149(4):1121-3. PubMed ID: 26319033
[No Abstract] [Full Text] [Related]
6. Therapy: Oral SMAD7 antisense oligonucleotide proves effective for Crohn's disease.
Ray K
Nat Rev Gastroenterol Hepatol; 2015 May; 12(5):251. PubMed ID: 25824998
[No Abstract] [Full Text] [Related]
7. Oral SMAD7 antisense drug for Crohn's disease.
Vermeire S
N Engl J Med; 2015 Mar; 372(12):1166-7. PubMed ID: 25785975
[No Abstract] [Full Text] [Related]
8. [Efficacy and Safety of an Oral SMAD7 Antisense Drug for Active Crohn's Disease].
Seo GS
Korean J Gastroenterol; 2015 Jun; 65(6):384-5. PubMed ID: 26288865
[No Abstract] [Full Text] [Related]
9. Reply: To PMID 25785968.
Monteleone G; Pallone F
Gastroenterology; 2015 Oct; 149(4):1123. PubMed ID: 26319031
[No Abstract] [Full Text] [Related]
10. CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide.
Marafini I; Monteleone I; Dinallo V; Di Fusco D; De Simone V; Laudisi F; Fantini MC; Di Sabatino A; Pallone F; Monteleone G
J Crohns Colitis; 2017 May; 11(5):603-609. PubMed ID: 28453765
[TBL] [Abstract][Full Text] [Related]
11. Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.
Monteleone G; Di Sabatino A; Ardizzone S; Pallone F; Usiskin K; Zhan X; Rossiter G; Neurath MF
Aliment Pharmacol Ther; 2016 Mar; 43(6):717-24. PubMed ID: 26766141
[TBL] [Abstract][Full Text] [Related]
12. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study.
Marafini I; Stolfi C; Troncone E; Lolli E; Onali S; Paoluzi OA; Fantini MC; Biancone L; Calabrese E; Di Grazia A; Monteleone I; Lenti MV; Di Sabatino A; Monteleone G
BioDrugs; 2021 May; 35(3):325-336. PubMed ID: 33871807
[TBL] [Abstract][Full Text] [Related]
13. Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases.
Laudisi F; Dinallo V; Di Fusco D; Monteleone G
Curr Drug Metab; 2016; 17(3):303-6. PubMed ID: 26651974
[TBL] [Abstract][Full Text] [Related]
14. Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
Monteleone G; Stolfi C; Marafini I; Atreya R; Neurath MF
Mol Diagn Ther; 2022 Sep; 26(5):477-481. PubMed ID: 35841457
[TBL] [Abstract][Full Text] [Related]
15. Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.
Boland BS; Vermeire S
Gastroenterol Clin North Am; 2017 Sep; 46(3):627-644. PubMed ID: 28838419
[TBL] [Abstract][Full Text] [Related]
16. Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment.
Arrico L; Stolfi C; Marafini I; Monteleone G; Demartis S; Bellinvia S; Viti F; McNulty M; Cabani I; Falezza A; Di Bari L
Nucleic Acid Ther; 2022 Aug; 32(4):312-320. PubMed ID: 35263186
[TBL] [Abstract][Full Text] [Related]
17. Editorial: mongersen in Crohn's disease--a new contribution to the beginning of a long-awaited therapeutic revolution?
Kirchgesner J; Sokol H
Aliment Pharmacol Ther; 2016 Apr; 43(7):838-9. PubMed ID: 26932411
[No Abstract] [Full Text] [Related]
18. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease.
Zorzi F; Calabrese E; Monteleone I; Fantini M; Onali S; Biancone L; Pallone F; Monteleone G
Aliment Pharmacol Ther; 2012 Nov; 36(9):850-7. PubMed ID: 22971085
[TBL] [Abstract][Full Text] [Related]
19. Smad7 antisense oligonucleotide-based therapy for inflammatory bowel diseases.
Zorzi F; Angelucci E; Sedda S; Pallone F; Monteleone G
Dig Liver Dis; 2013 Jul; 45(7):552-5. PubMed ID: 23287011
[TBL] [Abstract][Full Text] [Related]
20. Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease.
Ardizzone S; Bevivino G; Monteleone G
Therap Adv Gastroenterol; 2016 Jul; 9(4):527-32. PubMed ID: 27366221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
